IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study

Bagot, M.; Porcu, Pierluigi; William, Basem M.; Vermeer, Maarten H.; Whittaker, Sean; Wolff, Caroline; Khodadoust, Michael S.; Battistella, Maxime; Paiva, Christine; Sicard, Hélène; Azim, Hatem A.; Kim, Youn

doi:10.1016/j.ejca.2018.07.282

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As of June 28, 2018, the objective response rate was 36% and PFS was 8.2 months in the total study population. 27 It was noted SS patients in the dose-escalation arm (n = 20) showed a PFS of close to 1 year and better outcomes were observed in patients without histologic large-cell transformation (n = 29), with an objective response rate of 51.7% and PFS of 12.8 months. 27 Results for this trial are still being updated, and a phase 2 trial is being planned to start in the first half of 2019.…”

Section: Other Potential Therapeutic Targetsmentioning

confidence: 94%

See 1 more Smart Citation

Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma

Van‐de‐Velde

Zhou

2019

J Cutan Med Surg

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas characterized by an infiltration of malignant monoclonal T lymphocytes into the skin. Mycosis fungoides (MF), the most common subtype, and the rarer Sézary syndrome (SS), are considered the classical forms of CTCL, which, because of a varying presentation and lack of genetic and immunophenotypical markers, can often have a delayed diagnosis. With skin-directed topical treatment being the mainstay of therapy in the early stages, there is an absence of long-term curative therapies for advanced disease. Recent insight into the pathogenesis of CTCL has identified new potential therapeutic targets including the monoclonal antibody therapies, brentuximab vedotin and mogamulizumab. Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, received extended approval by the US FDA in 2017 to include primary cutaneous anaplastic large-cell lymphoma and CD30-expressing MF. Mogamulizumab, an anti-CCR4 antibody, received FDA approval in 2018 for relapsed or refractory MF and SS. Further targets and therapies continue to be investigated, including the monoclonal antibody therapy alemtuzumab, an anti-CD52 antibody, and the immune checkpoint blockade therapies, pembrolizumab and nivolumab. These new and emerging targets and therapies may lead to a promising broadening of CTCL treatment options in the future.

show abstract

Section: Other Potential Therapeutic Targetsmentioning

confidence: 94%

“…26 One multicentre, international phase 1 trial was undertaken involving IPH4102. 27 A total of 44 patients with relapsed or refractory CTCL who had previously been treated with a median of 3 prior systemic treatments were recruited. The trial consisted of 2 parts, a dose-escalation (n = 25) and cohort expansion (n = 19).…”

Section: Anti-kir3dl2 Iph4102mentioning

confidence: 99%